Serveur d'exploration sur les relations entre la France et l'Australie - Analysis (Canada)

Index « Auteurs » - entrée « L B A. Van De Putte »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
L Andres Sirulnik < L B A. Van De Putte < L B Ousager  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 1.
Ident.Authors (with country if any)Title
001A90 (2004) L B A. Van De Putte [Pays-Bas] ; C. Atkins [Canada] ; M. Malaise [Belgique] ; J. Sany [France] ; A S Russell [Canada] ; P L C M. Van Riel [Pays-Bas] ; L. Settas [Grèce] ; J W Bijlsma [Pays-Bas] ; S. Todesco [Italie] ; M. Dougados [France] ; P. Nash [Australie] ; P. Emery [Royaume-Uni] ; N. Walter [Allemagne] ; M. Kaul [Allemagne] ; S. Fischkoff [États-Unis] ; H. Kupper [Allemagne]Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed

List of associated KwdEn.i

Nombre de
documents
Descripteur
1ACR, American College of Rheumatology
1ANA, antinuclear antibody
1Abbott laboratories
1Adalimumab
1Adalimumab monotherapy
1Adalimumab treatment groups
1Adverse event
1Adverse events
1American college
1Antirheumatic drugs
1Arthritis
1Arthritis rheum
1Atkins
1Baseline
1Baseline value
1CRP, C reactive protein
1Concomitant
1Concomitant methotrexate
1DAS, disease activity score
1DMARDs, disease modifying antirheumatic drugs
1Disability index
1Disease activity
1Disease activity score
1Dmard
1Dmards
1Dos
1ESR, erythrocyte sedimentation rate
1EULAR, European League Against Rheumatism
1Erythrocyte sedimentation rate
1Eular
1Eular response
1Eular response rates
1European league
1Good eular response
1HAQ DI, Disability Index of the Health Assessment Questionnaire
1Health assessment questionnaire
1Injection site reaction
1MTX, methotrexate
1Methotrexate
1Monoclonal
1Monoclonal antibody
1Monotherapy
1NSAIDs, non-steroidal anti-inflammatory drugs
1Other week
1Patient assessment
1Percentage change
1Placebo
1Previous dmard treatment
1Primary efficacy
1Putte
1RA, rheumatoid arthritis
1Randomised
1Reactive protein
1Regimen
1Respective adalimumab doses
1Response criteria
1Response rates
1Rheum
1Rheumatoid
1Rheumatoid arthritis
1Rheumatology
1Riel
1Riel plcm
1Sample size
1Serious infections
1Significant difference
1Significant differences
1Study drug
1TNF, tumour necrosis factor
1Traditional dmards
1Treatment group
1Treatment groups
1Tumour necrosis factor
1adalimumab
1disease modifying antirheumatic drugs
1human monoclonal antibodies
1monotherapy
1rheumatoid arthritis
1tumour necrosis factor α

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Canada/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/Canada/Analysis/Author.i -k "L B A. Van De Putte" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Canada/Analysis/Author.i  \
                -Sk "L B A. Van De Putte" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Canada/Analysis/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Canada
   |étape=   Analysis
   |type=    indexItem
   |index=    Author.i
   |clé=    L B A. Van De Putte
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024